Tommaso Azzarito
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors.
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: March 07, 2017
Novel Instruments for the Implementation of Electrochemotherapy Protocols: From Bench Side to Veterinary Clinic.
Journal: Journal of cellular physiology
Published: June 19, 2016
Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: May 05, 2016
Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL Mice.
Journal: PloS one
Published: March 09, 2016
Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect.
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: May 29, 2015
Detection of exosomal prions in blood by immunochemistry techniques.
Journal: The Journal of general virology
Published: March 26, 2015
Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols.
Journal: Current cancer drug targets
Published: March 20, 2015
Exosomal clusterin, identified in the pericardial fluid, improves myocardial performance following MI through epicardial activation, enhanced arteriogenesis and reduced apoptosis.
Journal: International journal of cardiology
Published: January 29, 2015
Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: December 17, 2014
Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma.
Journal: Cancer letters
Published: August 01, 2014
TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells.
Journal: Oncogene
Published: April 09, 2014
Last Updated: 09/26/2026